A ntibiotic resistance in pathogenic bacteria poses a growing threat to human health, by increasing the mortality rate and economic burden associated with bacterial infections 1 . In light of this threat, there is an urgent need to develop new tools for predicting when resistance is likely to evolve in pathogen populations 2 . Research in this area has largely focused on understanding how differing antibiotic treatment strategies, such as mixtures and cycles, influence the evolutionary dynamics of resistance [3] [4] [5] . An alternative approach is to ask whether there are specific genes that make bacteria more likely to evolve resistance to antibiotics 6 . Whole-genome sequencing has highlighted the incredible genetic diversity of pathogenic bacteria 7 , but the impact of this diversity on the evolution of antibiotic resistance remains poorly understood. For example, recent work in Streptococcus pneumoniae has shown that genes that are important for resistance in one strain may be completely dispensable in another 8 . Although many genes are associated with clinical resistance, it is unclear to what extent other genes in the genome influence the evolution of resistance. For example, recent work has shown that some genes 'potentiate' the evolution of novel bacterial phenotypes by opening otherwise inaccessible routes to adaptation 9, 10 . The existence of potentiator genes suggests that genomic background may play a key role in the evolution of antibiotic resistance.
In vitro selection experiments have emerged as an important tool for studying the evolution of antibiotic resistance 1, 3, 5 . However, these studies typically use selection lines derived from a single ancestral clone, making it difficult to understand the role that genetic background itself plays in the evolution of resistance. One approach to circumvent this difficulty is to use comparative experimental evolution, where a diverse collection of strains are challenged with adapting to a common selective pressure 6, 11 . Using this approach, we recently demonstrated that genetic background influences the evolution of resistance to rifampicin by altering the spectrum and fitness effects of mutations in a highly conserved domain of RNA polymerase that confer resistance to rifampicin 6, 12 . In this paper, we extend this approach to uncover resistance potentiator genes by challenging eight strains that span the genus Pseudomonas with the β -lactam antibiotic ceftazidime.
Pseudomonas is a diverse genus of bacteria that includes P. aeruginosa-an important opportunistic pathogen of humans that is the primary cause of mortality in patients who suffer from cystic fibrosis. Crucially, it is possible to culture a wide range of Pseudomonas strains under a common set of laboratory conditions, allowing us to study evolutionary responses to antibiotics in these bacteria using tightly controlled and replicated experiments. We chose to study the evolution of resistance to ceftazidime for two reasons. First, ceftazidime is a clinically relevant antibiotic that is commonly used to treat Pseudomonas infections 13 and ceftazidime resistance is common in clinical isolates of P. aeruginosa. Second, the mechanisms of ceftazidime action and resistance are well characterized. Ceftazidime inhibits cell wall biosynthesis by irreversibly binding to periplasmic penicillin-binding proteins (PBPs), ultimately leading to cell death. In spite of this simple mechanism of action, Pseudomonas can use at least four routes to evolve resistance to ceftazidime: altering the structure of PBPs, upregulating the expression of efflux pumps, reducing the permeability of the outer membrane and upregulating the expression of β -lactamase enzymes that break down the antibiotic [14] [15] [16] ( Supplementary Fig. 1 ). Mutations altering the structure of the β -lactamase enzyme itself do occur, but provide much lower increases in resistance 17 .
We used a serial passage experiment to challenge close to 1,000 populations of Pseudomonas with doses of ceftazidime that increased from sub-lethal to lethal concentrations over the course of 1 week. We then used extensive whole-genome resequencing of evolved clones to identify genes and pathways that contribute to the rapid evolution of elevated ceftazidime resistance. Using selection experiments and competition assays with defined mutants, we directly tested the evolutionary impact of key pathways to resistance identified from whole-genome sequencing. Finally, we demonstrate that understanding the genetic drivers of resistance evolution can Identifying and exploiting genes that potentiate the evolution of antibiotic resistance Danna R. Gifford 1,3 *, Victoria Furió 1,3 , Andrei Papkou 1 , Tom Vogwill 1 , Antonio Oliver 2 and R. Craig MacLean 1 * There is an urgent need to develop novel approaches for predicting and preventing the evolution of antibiotic resistance. Here, we show that the ability to evolve de novo resistance to a clinically important β -lactam antibiotic, ceftazidime, varies drastically across the genus Pseudomonas. This variation arises because strains possessing the ampR global transcriptional regulator evolve resistance at a high rate. This does not arise because of mutations in ampR. Instead, this regulator potentiates evolution by allowing mutations in conserved peptidoglycan biosynthesis genes to induce high levels of β -lactamase expression. Crucially, blocking this evolutionary pathway by co-administering ceftazidime with the β -lactamase inhibitor avibactam can be used to eliminate pathogenic P. aeruginosa populations before they can evolve resistance. In summary, our study shows that identifying potentiator genes that act as evolutionary catalysts can be used to both predict and prevent the evolution of antibiotic resistance.
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be used to design a simple drug mixture, consisting of ceftazidime coupled to a β -lactamase inhibitor, to prevent the evolution of resistance in vitro.
Results and discussion
Strain-specific variation in resistance evolution. To test the role of genetic background in the evolution of antibiotic resistance, we challenged 120 populations of each of 8 strains that span the diversity of the genus Pseudomonas with ceftazidime ( Fig. 1a ). This breadth of phylogenetic coverage allowed us to explore the impact of genome content on resistance evolution, and strains were chosen on the basis of variation in genome size, experimental tractability and the availability of high-quality published reference genomes. Populations were serially passaged in standard laboratory culture medium supplemented with ceftazidime, the concentration of which was doubled daily from sub-lethal (1/8 minimum inhibitory concentration (MIC)) to super-lethal (8× MIC) levels over a 7 day selection experiment. The MIC of the parental strains varies (0.65-8 mg l -1 ) and we controlled for this variation by standardizing antibiotic doses of selection lines to their appropriate parental strains. In this experimental design, populations can only avoid extinction if they evolve elevated antibiotic resistance, and we measured population survival on each day of the experiment. We define the rate of population extinction within strains as a measure of adaptive potential for resistance evolution, or 'evolvability' . The rate of population extinction varied profoundly between strains ( Fig. 1b ; Cox's proportional hazard, likelihood ratio = 1,930, d.f. = 7, P < 10 −6 ). For example, all of the replicate populations went extinct in some strains, such as P. mendocina CCUG1781 and P. fulva CCUG12537, while at the other extreme, every population of P. protegens Pf-5 survived at up to 8× the MIC of the parental strain. Given that resistance evolved by selection on spontaneous mutations, one potential explanation for this result is that the ability to evolve ceftazidime resistance correlates with the mutation rate. However, evolvability does not correlate with mutation rate (Pearson correlation coefficient r = 0.33, F 1,6 = 0.74, P = 0.42; see Supplementary Table 1 for calculations) or mutation supply rate, which is the product of initial population size and mutation rate (r = 0.22, F 1,5 = 0.27, P = 0.62). Additionally, there was no correlation between survival and the absolute difference between the temperature of the selection experiment (30 °C) and published optimal growth temperatures for each strain (r = 0.06, F 1,6 = 0.027, P = 0.88).
Genomics of resistance evolution.
To determine the genetic basis of resistance evolution, we sequenced the genomes of 100 independently evolved clones from populations that survived selection for elevated resistance (n = 14-24 clones per strain). We identified a total of 196 novel mutations in 69 unique genes (that is, orthologues across strains were each counted once). Mutations included single nucleotide polymorphisms (SNPs; n = 80), short indels (n = 71), insertion element insertions (n = 15), larger insertions and deletions (n = 7) and intergenic mutations (n = 23). Several lines of evidence indicate that the mutations that we identified were predominantly beneficial. First, parallel evolution occurred both within and across strains. We identified a total of 25 genes mutated in two or more independent clones, and 76% of mutations occurred in these 25 genes. Second, all 80 SNPs observed in coding regions were non-synonymous, which is a clear hallmark of positive selection. A full list of the mutations we identified is given in Supplementary Table 2 . We categorized mutations according to known resistance mechanisms: (1) porin genes, (2) PBPs, (3) peptidoglycan biosynthesis genes and (4) multidrug efflux pumps [14] [15] [16] . Almost all of the evolved clones (88 out of 100) carry mutations in previously established ceftazidime resistance pathways. However, the distribution of mutations across these resistance pathways differs profoundly between strains, demonstrating strain-specific mechanisms of resistance evolution ( Fig. 2 ; χ 2 = 139, d.f. = 12, P < 10 −6 ). P. protegens Pf-5 and P. fluorescens Pf0-1 adapt by mutations in genes involved in peptidoglycan biosynthesis and recycling (ampD and mpl), knockouts of which are known to increase the expression of the chromosomal ampC β -lactamase gene 15, 18 . In addition to mutations in ampD and mpl, 21 of 24 clones of P. aeruginosa PAO1 carry mutations in a nonessential PBP (dacB/PBP4) that has also been shown to increase ampC expression when knocked out 18 . Consistent with these genetic data, clones from these strains have increased resistance to a broad spectrum of β -lactams, but retain sensitivity to imipenem, which is a poor substrate for the AmpC β -lactamase. In contrast, P. stutzeri ATCC17588 and P. putida KT2440 evolve resistance by mutations in efflux pump genes and, to a lesser extent, porins. Mutations in efflux pumps are associated with small increases in ceftazidime resistance and a multidrug-resistant phenotype, while porin mutations are predominantly associated with elevated β -lactam resistance (Fig. 2) . A substantial fraction (33.3%) of clones from these strains lack mutations in known resistance genes; however, these clones have resistance profiles that are similar to those of clones carrying mutations in known efflux pumps or porins.
The AmpR transcription factor increases evolvability. The key insight from whole-genome sequencing and phenotypic analysis of evolved clones is that large increases in ceftazidime resistance are associated with mutations in the peptidoglycan biosynthesis pathway associated with increased β -lactamase production 15 . Importantly, the relevant peptidoglycan biosynthesis genes (ampD, mpl and dacB) are present in all of the strains, and the ampC β -lactamase gene is present in all of the strains except P. stutzeri ATCC17588 (which possesses another β -lactamase gene, blaZ).
These observations raise an interesting puzzle: if the key genes involved in adaptation are largely maintained, why does evolvability 
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vary across strains? An alternative approach to understanding why evolvability varies across strains is to take a functional approach to characterizing the effects of beneficial mutations. Inactivation of the peptidoglycan biosynthesis genes involved in adaptation in our experiment has been shown to increase ampC expression by causing intracellular accumulation of peptidoglycan catabolites 15, 18 . However, ampC induction via this mechanism requires the AmpR transcription factor; inactivation of ampR removes the ability to increase ampC expression in response to β -lactams 18 . Crucially, among our strains, ampR is only present in the genomes of P. aeruginosa PAO1, P. protegens Pf-5, P. fluorescens Pf0-1 and P. fluorescens SBW25. This simple association between the presence of the AmpR transcription factor and the probability of survival to the end of the experiment through adaptation suggests that regulation of ampC expression is key.
How does ampR increase evolvability? One simple possibility is that this regulator potentiates evolution by opening up new genetic paths to evolving elevated ceftazidime resistance 9, 10 . Specifically, ampR could potentiate the evolution of ceftazidime resistance by allowing mutations in peptidoglycan biosynthesis genes, such as ampD, mpl and dacB, to increase levels of ampC expression. Consistent with this hypothesis, mutations in peptidoglycan biosynthesis genes and dacB are known to only increase resistance in the presence of ampR 18, 19 . This hypothesis generates two simple predictions that can be tested using our method. First, if elevated expression of ampC is a key mechanism for evolving ceftazidime resistance, deleting ampC should decrease evolvability. Second, if the AmpR regulator is required to drive the evolution of increased ampC expression, deleting ampR should reduce evolvability by the same amount as deleting ampC. To test these predictions, we challenged populations of Δ ampR and Δ ampC mutants of P. aeruginosa PAO1 with increasing doses of ceftazidime, as in our initial experiment ( Fig. 3a ). Both mutants have dramatically reduced evolvability compared with their isogenic P. aeruginosa PAO1 control (Cox's proportional hazard, likelihood ratio = 23.82, d.f. = 2, P = 6 × 10 −6 ), providing conclusive evidence that both the β -lactamase (ampC) and its regulator (ampR) play key roles in driving the evolution of elevated ceftazidime resistance.
The low survival probability of P. aeruginosa PAO1 in comparison with the other strains that carry both ampR and ampC is also consistent with this hypothesis. Strains of P. fluorescens and P. protegens carry two homologues of ampD, which represses the expression of ampC, whereas P. aeruginosa PAO1 carries three (8× MIC) . a, Black boxes show the presence of mutations in known ceftazidime resistance genes, as determined by wholegenome resequencing. Note that some clones carry mutations in multiple resistance genes and some clones lack mutations in known resistance genes (Supplementary Table 2 The ampR deletion reduces evolvability to levels comparable to those observed in a mutant lacking the ampC β -lactamase (PAO1::Δ ampC; n = 90). b, Relative fitness (mean ± s.e.m.; n = 9) of the PAO1::Δ ampR mutant (green triangles) and the PAO1::Δ ampC mutant (blue circles) in direct competition with a PAO1 reference strain carrying a neutral YFP marker. Symbols denote statistical significance, as determined by a Bonferroni-corrected Wilcoxon rank sum test (NS, not significant (P > 0.05); *P < 0.05; ***P < 0.001).
homologues of this gene. The additional copy of ampD found in P. aeruginosa ensures that ampD mutations lead to weaker derepression of ampC expression, and this is likely to translate into reduced evolvability compared with strains with only two ampD homologues; the ampD dosage effect has been demonstrated experimentally 19 . Consequently, most surviving P. aeruginosa strains possessed two loss of function mutations in the peptidoglycan biosynthesis pathway, compared with one only in the other ampR/ ampC-possessing strains (Fig. 2 ).
Additionally, it is possible that adaptive plasticity in ampC expression mediated by ampR could increase evolvability 21 . Exposure to β -lactam antibiotics interferes with peptidoglycan biosynthesis by inhibiting PBPs, causing an AmpR-mediated increase in ampC expression 18, 22 . This, in turn, may accelerate the genetic evolution of resistance by providing bacterial populations with the time to acquire ceftazidime resistance mutations. According to this explanation, ampR increases evolvability through ecological potentiation. The key assumption of this hypothesis is that the plasticity in ampC expression mediated by ampR must provide a benefit in the presence of ceftazidime. To test this hypothesis, we measured the effect of deleting ampR and ampC on fitness using short-term competition experiments (Fig. 3b ). Deleting ampC leads to a decrease in fitness in the presence of ceftazidime, demonstrating that induced expression of this gene is beneficial. However, deleting ampR actually increases fitness in the presence of sub-MIC concentrations of ceftazidime, demonstrating that plasticity in gene expression cannot explain the link between ampR and increased evolvability. Indeed, as ampR expression is not particularly strongly induced by ceftazidime 23 , this suggests that ampR does not simply allow populations to 'buy time' to wait for an adaptive mutation. Although this result is counter-intuitive, it is important to emphasize that AmpR is a global transcriptional regulator that affects the expression of hundreds of genes 24, 25 , including repressing another chromosomal β -lactamase, poxB 25 . In particular, AmpR is involved in regulating quorum sensing factors (including lasR), several metabolic pathways and the rpoS-mediated stress response pathway 25 . Although it is clear that inducing elevated levels of ampC expression in the presence of ceftazidime is beneficial, the fitness cost associated with the ampR regulator gene implies that the net fitness effect of all of the changes in gene expression caused by this regulator in the presence of ceftazidime is deleterious. The importance of AmpR as a global regulator of expression perhaps explains why increased ampC expression did not arise through mutations in ampR itself, and why ampR mutations are not typically observed in clinical P. aeruginosa isolates 26 .
Inhibiting the evolution of ceftazidime resistance. Given the important role that AmpR-mediated induction of ampC expression plays in the evolution of resistance, our results suggest that one possible strategy to prevent the evolution of cephalosporin resistance in P. aeruginosa infections would be to co-administer ceftazidime with AmpC β -lactamase inhibitors 27 . The rationale for this strategy is that a combination of a β -lactam and β -lactamase inhibitor will be active against both wild-type bacterial strains and mutants with elevated β -lactamase secretion. In other words, this strategy should effectively block a major evolutionary path to elevated resistance. To test this idea, we challenged P. aeruginosa PAO1 with ceftazidime in the presence of avibactam 28 , a recently developed AmpC inhibitor (Fig. 4a) . Unlike most β -lactamase inhibitors, avibactam does not possess any toxic effects on Pseudomonas 28 and we did not detect any population extinction in the avibactam-treated control populations. In support of our hypothesis, avibactam increased the rate of population extinction in the presence of ceftazidime compared with ceftazidime-treated control populations (Cox's proportional hazard, likelihood ratio test = 78.968, d.f. = 1, P < 10 −6 ). We failed to detect any viable cells in 59 out of 60 populations of P. aeruginosa that were selected in 8× MIC ceftazidime supplemented with avibactam, demonstrating that the effect of avibactam suppresses the evolution of elevated β -lactamase secretion just as effectively as knocking out ampC or ampR (Fig. 3a) . Importantly, this effect does not arise because avibactam increases the potency of ceftazidime. Surprisingly, we found that avibactam treatment actually increased the MIC of ceftazidime from 0.76 to 1.14 mg l -1 ( Supplementary Fig. 2) .
As a final test of the role of ampR in evolvability, we challenged populations of Δ ampR (Fig. 4b ) and Δ ampC (Fig. 4c ) mutants of P. aeruginosa PAO1 with a combination of ceftazidime and avibactam, as in our experiment with wild-type P. aeruginosa PAO1. Avibactam had no effect on evolvability in either Δ ampR or Δ ampC mutants (Cox's proportional hazard, likelihood ratio test = 3.25, d.f. = 1, P = 0.071; likelihood ratio test = 0.02, d.f. = 1, P = 0.876, respectively), showing that these strains were effectively unable to increase ampC expression under our experimental conditions.
Conclusion
Whole-genome sequencing is revolutionizing our understanding of the evolution and ecology of bacterial pathogens. One of the challenges that has arisen from this revolution is the ability to understand the consequences of genetic diversity in pathogen populations. Here, we show that comparative experimental evolution can be used to identify genes and pathways that influence the rate and mechanisms of adaptation to antibiotics. Our experiment addressed this problem at a fairly broad scale by comparing the evolutionary responses of strains from different species. Our initial reasoning for working at this scale was that comparing divergent strains effectively maximizes the number of genes and SNPs that are included in the experiment, therefore maximizing the likelihood of detecting an impact of genetic background on evolvability. However, the sheer number of genetic differences between even the most closely related strains used in this study may have hindered our ability to detect more subtle genomic effects on evolvability. While it is clear that inducible ampC β -lactamase expression is an important driver of evolvability in this genus, it is also clear that other genes must influence the ability to evolve ceftazidime resistance. For example, P. stutzeri ATCC17588 and P. putida KT2440, both of which lack ampR, have similar evolvability to P. aeruginosa PAO1. We are currently extending this research programme by focusing on studying variation in evolvability between clones from the same species, and we hope that this approach will enable us to identify genetic drivers of evolvability in greater depth.
The differing modes of ampC expression among the pseudomonads affect their ability to evolve resistance to β -lactams by interacting with genes in the peptidoglycan biosynthesis pathway. In strains possessing ampR, the intracellular accumulation of peptidoglycan catabolites converts the AmpR transcription factor into an activator of ampC expression in response to peptidoglycan damage. Mechanistically, ampR increases evolvability by allowing mutations in peptidoglycan biosynthesis genes to induce high levels of β -lactamase expression, which effectively amplifies the ampC expression plasticity that occurs when cell wall synthesis is compromised by β -lactams 20 . From a more conceptual perspective, ampR can be thought of as a conduit that translates genetic variation in the peptidoglycan biosynthesis gene network into phenotypic variation in ampC expression. This suggests that response pathways that are involved in sensing environmental change may have a general role as evolutionary catalysts, linking plastic and mutational responses to environmental change. Intriguingly, these alternative expression modes are disseminated among the enterobacteria; however, insertion of the ampR gene into constitutive producers is not sufficient to restore inducible expression, suggesting a distinct regulatory mechanism in constitutive producers 29 . To avoid the evolution of high NaTure eCology & evoluTIoN levels of ceftazidime resistance and subsequent treatment failure, treatment with ceftazidime should be avoided in infections caused by strains with inducible ampC expression.
Understanding the evolutionary trajectory to high levels of ceftazidime resistance makes it possible to design a simple two-drug mixture consisting of ceftazidime and avibactam that can be used to effectively eliminate populations of the pathogen P. aeruginosa. We argue that this strategy is successful because avibactam effectively prevents mutations in peptidoglycan biosynthesis genes and dacB from increasing ceftazidime resistance, eliminating their fitness benefit. One possible solution to this evolutionary challenge would be to first evolve avibactam resistance and then evolve ceftazidime resistance. However, avibactam does not have any detectable toxic effects on Pseudomonas at concentrations where it is able to effectively inhibit AmpC, rendering this evolutionary pathway to combined avibactam/ceftazidime resistance inaccessible. Although these results are encouraging, we emphasize that there are a number of confounding factors that may affect the efficacy of this combination of drugs in vivo. For example, the pharmacokinetic properties of the two drugs may make it difficult to effectively maintain the drug mixtures at the site of bacterial infections and it is also possible that avibactam-resistant alleles of ampC or other β -lactamases capable of hydrolysing ceftazidime are already present in pathogen populations.
Predicting the evolution of antibiotic resistance is a challenging and important objective. Here, we show that comparative experimental evolution can be used to identify genes and pathways that make some bacterial strains prone to evolving resistance, and to exploit this to design treatment strategies for preventing resistance evolution. High-throughput sequencing is revolutionizing clinical microbiology 30, 31 , and it may be possible to identify such potentiator genes in clinical pathogen populations and to use this information to optimize antimicrobial treatment strategies.
Methods

MIC determination for parental strains.
Three independent estimations of the MIC for each parental strain were determined in 96-well plates using the broth microdilution method. Briefly, 5-10 morphologically similar colonies of each strain were resuspended in sterile saline solution (NaCl 0.9%). The solution was adjusted to the adequate optical density so that it would contain approximately 1.5 × 10 8 cells ml -1 . This standardized inoculum was diluted a further 200-fold in Mueller-Hinton 2 (MH2; Sigma-Aldrich) broth containing ceftazidime (Sigma-Aldrich) at a concentration between 64 mg and 0.0625 mg l -1 . After 24 h of incubation at 30 °C with shaking at 250 r.p.m., optical density at 595 nm was determined for each well with a Synergy 2 plate reader (BioTek). We considered that bacterial growth had been inhibited if the optical density was less than 25% of that of antibiotic-free cultures. The lowest antibiotic concentration at which growth had been inhibited was considered the MIC. The measured MIC was used to calculate the ramping ceftazidime concentration regime in the selection experiment (see 'Experimental evolution').
Effect of avibactam on MIC.
The effect of avibactam on MIC was evaluated by measuring growth inhibition by ceftazidime in the presence/absence of avibactam. The procedure was identical to MIC determination, as described above, except that one group of replicates was supplemented with 4 mg l -1 of avibactam (BioVision). No avibactam was added to the control group. The avibactam treatment and control groups were tested at concentrations ranging from 0.1 to 3.8 mg l -1 of ceftazidime with 4 replicates each.
Mutation rate estimation. Mutation rates were estimated by fluctuation assays, with the antibiotic rifampicin as the selection agent, using the method described in ref. 32 . Replicate cultures (n = 480) were inoculated with approximately 50 cells from an overnight culture of each parental strain and incubated for 48 h in 200 µ l of King's B media at 30 °C with constant shaking at 200 r.p.m. Approximately 10 7 cells from each culture were then plated onto King's B agar containing rifampicin at the appropriate MIC for each strain (60 mg l -1 for P. aeruginosa PAO1; 30 mg l -1 for all other strains). For each strain, the proportion of cultures yielding no mutants was scored, from which the mutation per culture was calculated using the negative natural logarithm. This value was then divided by the number of cells plated, which provided an estimate of the mutation rate per cell division.
Experimental evolution.
To initiate the selection experiment, all parental strains were recovered from − 80 °C stocks and cultured overnight in MH2 broth at 30 °C for 24 h with shaking at 250 r.p.m. Next, the cultures were diluted by 10 −6 in MH2 broth and distributed on 96-well plates (200 μ l per well). After 48 h of incubation at 30 °C, we initiated the first transfer by diluting these cultures 1:100 in MH2 broth containing 1/8 MIC of ceftazidime, relative to the measured MIC of each strain. Bacterial populations were incubated for 24 h at 30 °C with shaking at 250 r.p.m. and diluted 1:100 for the next transfer. Every transfer ceftazidime concentration was doubled, reaching 8× MIC in the final transfer. Population survival was monitored during the course of the selection experiment by measuring optical density at 595 nm using a Synergy 2 Microplate Reader (BioTek). We additionally confirmed population survival after the last transfer by plating a 1 μ l sample of each population on antibiotic-free MH2 agar plates that were scored for growth after overnight incubation at 30 °C. We performed the evolution experiment in two independent blocks. In each block, we propagated 60 replicate populations of each strain that were challenged with increasing doses of ceftazidime, as well as 12 replicate control populations of each strain that were allowed to evolve in antibiotic-free MH2. At the end of the experiment, a maximum of 20 populations per strain were streaked in MH2 agar plates and a clone was picked for each population and amplified for further analyses. To avoid bias by conducting the experiment at different temperatures and incubators, a common growth environment (that is, 30 °C, MH2) and growth medium (MH2) that supports the growth of all strains was chosen for all strains. Although the strains have different optimal growth temperatures (28 °C for P. protegens, P. fluorescens and P. fulva; 30 °C for P. putida and P. mendocina; 35 °C for P. stutzeri; and 37 °C for P. aeruginosa), all were capable of vigorous growth in this environment, hence the number of generations per day (6-7) was instead dictated by the dilution factor (1/100).
Experimental evolution with ∆ampC and ∆ampR mutants. We obtained ∆ ampC and ∆ ampR mutants of P. aeruginosa PAO1 that were constructed following well-established procedures based on the cre-lox system for gene deletion and 
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A A A A PAO1::ΔampC PAO1::ΔampR Antibiotic concentration (factor of MIC) Fig. 4 | Blocking the evolution of ceftazidime resistance. a, Survival of populations of P. aeruginosa PAO1 that were challenged with increasing doses of ceftazidime in either the presence or absence of the AmpC inhibitor avibactam (n = 60 populations per treatment). Avibactam was administered at a constant, non-inhibitory dose (4 mg l -1 ). b,c, Survival of ampR or ampC deletion strains (PAO1::Δ ampR and PAO1::Δ ampC, respectively) under the same experimental conditions as for the isogenic wild-type POA1 in a (n = 60 populations per treatment for each strain).
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antibiotic resistance marker recycling 33 . We determined the MIC of these mutants using the microbroth dilution method, as above. To test evolvability of ∆ ampC and ∆ampR mutants, we followed the same protocol as the main selection experiment, as outlined above. We challenged 90 replicate populations of each deletion mutant and 30 replicate populations of PAO1 wild-type with increasing doses of ceftazidime. In addition, we evolved 18 control populations per strain in antibioticfree culture medium. This experiment was carried out in a single block.
Experimental evolution to test the effect of avibactam. The effect of avibactam on evolvability was tested for Δ ampC and Δ ampR mutants and for wild-type PAO1. Replicate populations (n = 120) of each strain were passaged following exactly the same procedure as in the two previous experiments. The ceftazidime concentration was doubled every transfer from 1/8 to 8× MICs. For each strain, half of the populations (60 replicates) were additionally challenged with avibactam (always 4 mg l -1 ; BioVision). Population survival was monitored for seven serial transfers by measuring optical density. We also included 20 control populations evolving in the presence of avibactam but without the antibiotic. No extinction was observed in the control treatment.
Inhibition zone assays. Evolved clones were cultured in MH2 broth overnight (30 °C, 250 r.p.m.). A sterile swab was then dipped into a 10 -3 dilution of this overnight culture and used to inoculate the surface of three MH2 agar plates. Then, we placed 4 different antibiotic susceptibility testing discs (Oxoid) on each plate, testing a total of 12 antibiotics: ceftazidime, piperacillin, meropenem, imipenem, aztreonam, cloramphenicol, tetracycline, rifampicin, amikacin, tobramycin, ciprofloxacin and levofloxacin. After 24 h of incubation at 30 °C, the diameter of the different inhibition zones was measured with a ruler, taking the average of three measurements along different axes. Assays were performed in four randomized blocks containing a similar number of evolved clones for each strain, and all ancestral strains were tested in each block as a control. Change in antibiotic sensitivity was estimated as the difference in diameter of the inhibition zone of each clone compared with its ancestor for each antibiotic.
DNA extraction and sequencing. DNA from the evolved clones surviving the duration of the experiment was extracted using the Wizard Genomic DNA Purification Kit (Promega) as per the manufacturer's instructions. To maximize phylogenomic coverage and reduce bias towards P. fluorescens strains, P. fluorescens SBW25 was excluded from sequencing due to it being highly similar to P. fluorescens Pf0-1. We assessed the purity of DNA extractions by measuring absorbance at 230, 260 and 280 nm and visualizing migration on a 0.7% agarose gel. The concentration of each genomic DNA in each sample was then accurately determined using a QuantiFluor dsDNA System (Promega), and samples were diluted to 30 ng μ l -1 in Tris-EDTA buffer before sequencing.
Resequencing was performed using an Illumina HiSeq 2000 system with 100-base pair (bp) paired-end reads (Wellcome Trust Centre for Human Genetics). Sequencing analysis was performed using the pipeline first described in ref. 34 . Read filtering was done using the NGS QC Toolkit 35 . Read ends were trimmed if the Phred quality score was less than 20. We discarded reads < 50 bp after trimming, with > 2% ambiguous bases or with > 20% bases of Phred score < 20. The Burrows-Wheeler Aligner (http://bio-bwa.sourceforge.net/) 36 was used to map reads to the reference genome of each strain. Mapped reads were processed to increase the quality of the variant calling: (1) reads with multiple best hits were discarded; (2) duplicated reads were discarded using MarkDuplicates from the Picard package (https://broadinstitute.github.io/picard/); (3) reads around indels were locally realigned using RealignerTargetCreator and IndelRealigner from the GATK package to correct for misalignment; and (4) mate pairs were sorted using FixMateInformation in the Picard package. Variant calling was performed with GATK UnifiedGenotyper 37 and SAMtools mpileup 38 . VCFtools vcf-annotate 39 and GATK toolkit VariantFiltration 40 were used to filter the raw variants for strand bias, end distance bias, base quality bias, SNPs around gaps, low coverage and erroneously high coverage. Variants were combined using GATK's CombineVariants (keeping any unfiltered). High-quality variants not filtered were annotated using SnpEff 41 . Three approaches were used to detect structural variants: BreakDancer 42 (indels, inversions and translocations), Pindel 43 (indels, inversions, tandem duplications and breakpoints) and Control-FREEC (copy number variants 44 with mappability tracks generated by gem-mappability (GEM library 45 ).
Comparative genomics of resistance pathways. Using pairwise reciprocal BLAST between the reference sequences of the sequenced strains, we determined their similarity in genome content. This approach was taken because the strains differed in the extent to which their genomes were annotated. Using the KEGG database 46 , we compared the genes in the β -lactam resistance and peptidoglycan recycling pathways (irrespective of whether they had mutated during selection).
Competition experiment with ∆ampC and ∆ampR mutants. To measure the relative fitness of the deletion mutants, we performed a competition experiment. ∆ ampC, ∆ ampR and their isogenic PAO1 wild-type were competed against a yellow fluorescent protein (YFP)-marked tester PAO1 strain that carries a constitutively expressed YFP integrated at the mini-Tn7 insertion site 15 .
Competition experiments were carried out in MH2 broth containing ceftazidime at a concentration of 0, 0.25 or 0.5 mg l -1 . All competition experiments were replicated nine times. First, the strains were recovered from − 80 °C stock and cultured overnight in MH2 broth medium at 30 °C with shaking at 250 r.p.m. The overnight cultures were diluted 1:50 in MH2 broth and used to prepare 1:1 mixtures of PAO1-YFP with each of the three strains to be tested. Before starting competition, we first estimated the exact starting proportion of strains using flow cytometry (for details, see below). Next, we combined 10 µ l of these mixtures and 190 µ l of MH2 with a corresponding ceftazidime concentration (0, 1/4 and 1/2 MICs). This resulted in an additional 1:20 dilution. The bacterial strains were left to compete in 96-well plates for 24 h at 30 °C. The next day, the cultures were diluted 1:50 in saline solution (0.9% NaCl) and analysed on a flow cytometer to estimate the resulting proportion of the YFP-labelled versus unlabelled cells after competition (see below).
Flow cytometry was performed on an Accuri C6 flow cytometer (BD Biosciences). The cell densities were adjusted to give around 1,000 events per second. During data acquisition, a lower cut-off was set at 10,000 for forward scatter height and at 8,000 for side scatted height. The data were exported as flow cytometry standard files (FCS version 3.0) and processed in R using a custom pipeline based on flowCore and flowViz packages [47] [48] [49] . In the pipeline, the events were automatically gated on size by retaining the cells within two s.d. around the median in the bivariate normal distribution of forward scatter area and side scatter area. Then, the k-mean clustering algorithm was applied on fluorescence intensity height, excited by a 488 nm laser and measured through a 533 ± 30 nm bandpass filter, to differentiate fluorescent versus non-fluorescent cells. For each antibiotic concentration, we ensured that YFP-expressing strain could be well separated from non-fluorescent strains by overlaying non-mixed controls (overlap is usually less than 2% of the cells). Supplementary Fig. 3 shows a representative plot of the gating strategy.
Relative fitness was calculated according to the formula
where p 0 is an initial proportion of an unlabelled stain and p 1 is a final proportion of an unlabelled stain after competition. The number D = 1,000 is a dilution factor, which reflects a difference in cell density at the beginning and at the end of the competition.
Reporting Summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this article.
Data availability. The data that support the findings of this study are included within the paper and its Supplementary Information, with the exception of sequence data, which are deposited in the Eurpoean Nucleotide Archive (PRJEB20060).
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Experimental design 1. Sample size
Describe how sample size was determined. Sample size was chosen to optimize detection of differences in proportion, such that e.g. the minimum difference that could be detected with power 0.8 was 0.07 for proportions at the extremes where the variance is lowest (e.g. or p=1 vs p=0.93), and 0.18 for proportions around p=0.5 where variance is highest (e.g. p=0.41, p=0.59)
Data exclusions
Describe any data exclusions.
To increase the breadth of phylogenetic coverage, genomes from the strain SBW25 were excluded due to its similarity with strain Pf0-1
Replication
Describe whether the experimental findings were reliably reproduced.
All attempts at replication were successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Bacterial cells were distributed randomly from a larger population of cells to initiate selection lines.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Control (i.e. no antibiotic) and treatment groups within each strain were transferred blinded.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
